Premaitha closes deal on Yourgene acquisition
January 11, 2017Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
Yourgene has a commercial hub in Singapore and annual sales of circa £2.0 million generated from across South East Asia and India, and is broadly break-even at these trading levels.
The conditional acquisition was announced on December 21, 2016. New ordinary shares of 0.1p each are expected to be admitted to trading on AIM on January 11, 2017.
To remind, the announcement from December stated that on completion of the acquisition, directros of Yourgene Dr Bill Chang and Alan Chang will be appointed to the Board of Premaitha as Chief Scientific Officer and Non-executive Director respectively.
